USFDA flags eight issues with Ipca Labs; issues Form 483 after investigation
The American regulatory authority has issued 11 objections to the API plant of Ratlam, Madhya Pradesh, on June 14.
)
USFDA flags eight issues with Ipca Labs: The US Food and Drug Administration (USFDA) has found eight issues with Ipca Labs in its inspection of the company's facilities in Indore and Pithampur. After finding objections with the company's facilities at different places, the FDA has also issued Form 483 to the company.
USFDA conducted investigation between June 15 and 23 and found objections with the company's facilities in Ratlam, Indore, and Pithampur.
It tested at the company's formulations manufacturing facility at Pithampur and issued Form 483 after finding 8 objections.
TRENDING NOW
The American regulatory authority also found 11 objections at the API plant of Ratlam., which was inspected from June 5 to June 13.
Import Alert
After the FDA investigation, Ipca Labs' facilities in Ratlam and Pithampur are under an import alert.
The US regulatory body said that the company needed to resolve the objections the FDA has raised in Form 483.
It further said that the Ratlam and Pithampur facilities require clean chit for recovery in the US generics business.
Among the prominent objections, that the FDA found were: the company's failure in the quality unit associated with the API batch; its lack of consistency in processing condition, which raises critical quality questions regarding the quality; lack of efficiency in maintaining record properly.
01:53 pm
IPCA Lab stock trades flat post-Q4 announcement
Lyka Labs shares hit new 52-week high after Ipca Laboratories acquires 48 lakh shares of the company
IPCA Laboratories share price: Sharekhan maintains Buy recommendation with price target of Rs 2560
CLSA on Cipla, Glenmark, Cadila Healthcare, IPCA Labs and Lupin | What did not work for them and what did
Dr Reddy's Labs, Cadila Healthcare, Alkem Labs, Cipla to IPCA Labs, all you need to know about Pharma Sector